AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04529356 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen is used as the painkiller to alleviate patients' headache before and during the clinical trial. In order to decrease the medication bias, we required these patients to only use acetaminophen instead of other non-steroid anti-inflammatory drugs. In the meantime, participants are requested to recorder the frequency and dosage of acetaminophen they used during the treatment course.
Study NCT04529356 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen is used as the painkiller to alleviate patients' headache before and during the clinical trial. In order to decrease the medication bias, we required these patients to only use acetaminophen instead of other non-steroid anti-inflammatory drugs. In the meantime, participants are requested to recorder the frequency and dosage of acetaminophen they used during the treatment course.
Study NCT02351427 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: In one group, investigators administer bortezomib and steroid to manage acute cellular rejection in kidney transplantation, and compare the results with another group in which only steroid was administered.
Study NCT02351427 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroid
Description: Investigators administer steroid in both groups for conventional treatment of acute cellular rejection.
Study NCT01207271 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy
Description: 16 sessions of cognitive therapy administered weekly by a community mental health therapist
Study NCT01207271 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive-Expressive Psychodynamic Therapy
Description: 16 sessions of supportive-expressive psychodynamic therapy administered weekly by a community mental health therapist
Study NCT01639833 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Veriset Hemostatic Patch
Description: Topical hemostat
Study NCT01639833 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TachoSil®
Description: Topical Hemostat
Study NCT04397705 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patient Status Engine
Description: Wearable sensors
Study NCT03439709 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Gamma knife radiosurgery
Description: Minimum 25 Gy of marginal dose is applied for residual tumor or resection cavity. Depending on the size of tumor, the dose can be varied.
Study NCT03439709 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lanreotide 60Mg Solution for Injection
Description: Lanreotide injection.
Study NCT03439709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide 60Mg Solution for Injection
Description: Lanreotide injection.
Study NCT04516473 — intervention group
Intervention type: PROCEDURE
Intervention: Abdominal Body Contouring
Description: These are surgeries that correct for excess skin and its adverse consequences. The surgeries that focus on central area to remove a large hanging pannus is usually called panniculectomies or abdominoplasties; the former is focused on the excision of excess tissue to relieve impairment while the latter is generally considered a cosmetic surgery. The form of the surgery is case dependent and can range from removing apron of skin to complete contouring of the abdomen with tightening of the abdominal muscle and moving the belly button.
Study NCT03033745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IgPro20
Description: A liquid formulation of normal human IgG at a concentration of 20% administered as a subcutaneous infusion at a dose prescribed by subject's physician prior to study entry.
Study NCT01238939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NK012 and 5-FU
Description: NK012 infusion on Day 1 of each 28 day cycle 5-FU continuous infusion on Days 1 and 15 of each 28 day cycle
Study NCT00343512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Docetaxel 75 mg/m2 IV (1-hour infusion) on day 1 of each cycle (cycle = 2 weeks) x 4 cycles
Study NCT00343512 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis
Description: protein expression analysis
Study NCT00343512 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: laboratory biomarker analysis
Study NCT00343512 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: biopsy
Study NCT00343512 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: conventional surgery
Study NCT00343512 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Description: neoadjuvant therapy
Study NCT02755194 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study. The exposure of interest includes taking specific prescribed medications during breastfeeding.
Study NCT02738658 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold
Study NCT02738658 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus-eluting stent
Study NCT01499017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06291874 or placebo
Description: PF-06291874 will be administered as an extemporaneously prepared suspension for all doses within the initially planned range of 3 mg to 100 mg. Correspondingly, placebo doses will be administered as suspension.
Study NCT01499017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06291874 or Placebo
Description: PF-06291874 will be administered as an extemporaneously prepared suspension for all doses within the initially planned range of 300 mg to 650 mg. Correspondingly, placebo doses will be administered as suspension.
Study NCT01114529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Early CNI to everolimus conversion
Study NCT01114529 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf or Neoral
Description: Active CNI-based control (Prograf or Neoral)
Study NCT02678715 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Solubrux®
Description: prefabricated device adaptable by temperature
Study NCT02678715 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Customized Appliance
Description: customized device fabricated in the dental laboratory
Study NCT02678715 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Somatics®
Description: standard device
Study NCT03979157 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multispectral Optoacoustic Tomography
Description: Non-invasive transcutaneous imaging of subcellular muscle components
Study NCT02889458 — intervention group
Intervention type: OTHER
Intervention: Not Provided
Study NCT02103868 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco Cessation Counseling
Description: Doing group and personal counseling for tobacco cessation
Study NCT01055002 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood stage parasite (BSP) inoculum
Description: Inoculum of human red blood cells infected with falciparum malaria administered intravenously on Day 1
Study NCT02614079 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DSSEP
Description: Collision testing after the placement of SCS leads
Study NCT01699087 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photorefractive keratectomy (PRK)
Description: In this corneal surgical procedure, the outer corneal epithelial layer will be removed, after which the corneal stroma will be reshaped by excimer laser ablation to reduce or eliminate refractive errors.
Study NCT01699087 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ALLEGRETTO WAVE EYE-Q excimer laser system
Description: The ALLEGRETTO WAVE EYE-Q excimer laser system is used for corneal stroma reshaping during PRK surgery
Study NCT03729947 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Subfascial closed suction drain
Description: Ch 14 closed suction drain
Study NCT03729947 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Subfascial closed suction drain
Description: Ch 14 closed suction drain
Study NCT02499029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: NAC pills were administered each week. NAC is a N acetyl pro-drug of the naturally-occurring amino acid cystine. NAC is a white, crystalline powder with the molecular formula C5H9NO3S and with a molecular weight of 163.2.
Study NCT02499029 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical looking placebo pills were administered each week.
Study NCT02639663 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dental device
Description: Leboride~1. Post-partum primi and multiparous women whom are interested in breastfeeding and have not begun yet. This arm will be randomized into 2 groups~   1. Intervention group: participants will receive the dental device and be instructed to use it during breastfeeding.~  2. Control group: participants will not receive any device for breastfeeding pain control~2. Post-partum women that have already begun breast feeding, will receive the dental device and each woman will be serve as her own control (breastfeeding before and after the use of the dental device.
Study NCT02623335 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: QPL (question prompt list) brochure
Description: The QPL intervention includes the QPL intervention brochure, plus a letter from the surgeon encouraging its use during the upcoming office visit. Intervention materials will be mailed in advance of the patient's appointment with an enrolled surgeon.
Study NCT00090545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 43-9006
Description: 400 mg BAY 43-9006 orally twice daily in 28 day cycles.
Study NCT03683394 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMARRT Intervention
Description: Interventionists will follow a standard protocol for delivering the SMARRT intervention that allows for personalization of the specific risk reduction action plan; these plans will evolve over time according to participant progress, motivation and preferences or newly identified risk factors. Staff will use a tracking database to record information for each participant, including session dates, identified risk factors, motivational barriers and important values, and the outcome of discussions around developing goals. For each participant, the exact number and mode (phone or in-person) of contacts will differ, but we will aim to have at least 1 contact per month with each participant. Best practice will include in-person meetings twice a year during the 2-year intervention period.
Study NCT03683394 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education Intervention
Description: Participants randomized to the Health Education (HE) group will receive mailed materials (typically 1-2 pages) every 3 months. This will include general information on Alzheimer's and dementia risk reduction using materials from sources such as the Alzheimer's Association and educational materials commonly provided as part of routine care at Kaiser Permanente Washington (KPWA).
Study NCT01450982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-38518168 / MTX
Description: Day 1: MTX: Route=oral use, single dose of participant's weekly MTX dose
Study NCT01681420 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV Counseling and Testing
Description: HIV counseling and testing in lieu of blood donation.
Study NCT01681420 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blood Donation
Description: Blood donation without HIV counseling
Study NCT03176082 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mailed Reminders with Fecal Immunochemical Testing kits
Study NCT03176082 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reminder letter only
Study NCT00063401 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab:
Description: 400 mg/m2 loading dose, 250 mg/m2 weekly, six 21-day cycles
Study NCT00063401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m2 Day 1, six 21-day cycles
Study NCT00063401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC = 6 Day1, six 21-day cycles
Study NCT03665051 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Muscle Tissue Biopsy
Description: A biopsy of the Vastus Lateralis muscle will be performed on the left leg using the Bergstrom technique.The skin will be incised (approximately 0.75 cm) with a #11 scalpel, and the Bergstrom needle will be inserted into the Vastus Lateralis. Approximately 150 mg of muscle tissue will be obtained under suction. After the biopsy, pressure will be applied to stop bleeding and the skin will be closed with Steri strips (suture(s) if allergy to steri strips and removal 7-10 days post biopsy). A sterile dressing will be applied. Ace bandage may also be used along with applied pressure and an ice pack for any swelling and pain relief.
Study NCT03665051 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Maximal Oxygen Consumption (V02max)
Description: Aerobic fitness will be determined by measuring maximal O2 consumption (VO2max) during a stationary bicycle exercise test. Heart rate, blood pressure and ECG will be recorded throughout this test. Subjects will breathe through a low resistance mouthpiece and wear a nose clip. Expired gases will be measured by indirect calorimetry and heart rate monitored by a portable heart rate monitor. Following a standardized warm up, subjects will begin exercising at a moderate intensity with the workload increased every minute until the subject can no longer continue. A leveling-off (plateau) or decline in oxygen uptake should be demonstrated in order to be reasonably sure that a subject has achieved the maximum capacity for aerobic metabolism.
Study NCT02849756 — intervention group
Intervention type: OTHER
Intervention: older in intensive care unit
Description: It is an observational study with no intervention.
Study NCT00570102 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: A highly hydrolyzed formula
Description: Weaning to a highly hydrolyzed formula, avoidance of all supplemental food containing cow's milk proteins and/or bovine serum albumin up to the age of 6-8 months
Study NCT00570102 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: A regular cow's milk based formula
Description: Weaning to a regular cow's milk based formula supplemented with 20% of the highly hydrolyzed formula used in arm 1 to make the study formulas similar in smell and taste, avoidance of all supplemental food containing cow's milk proteins and/or bovine serum albumin
Study NCT03419715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost Topical Solution
Description: One drop of bimatoprost topical solution is applied daily to the lunula region of the fingernail bed
Study NCT03419715 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: One drop of saline solution is applied daily to the lunula of the fingernail bed on one hand.
Study NCT02087787 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BMT Legal Clinic
Description: 2 hour consultation with an attorney in the BMT Legal Clinic with potential follow-up as needed.
Study NCT03783260 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Description: During both Mediterranean diet periods, participants will be provided with meals and snacks representative of the Mediterranean nutritional habits. Participants will be required to eat only the meals provided.
Study NCT04203485 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Camrelizumab 200mg
Description: Camrelizumab 200mg q2w ivgtt
Study NCT04203485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate 250mg
Description: Apatinib Mesylate 250mg po qd
Study NCT04203485 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed disodium for injection
Description: Pemetrexed disodium for injection 500 mg/m2 q3w
Study NCT04203485 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel injection
Description: Paclitaxel injection 175 mg/m2 q3w
Study NCT04203485 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin AUC 5 mg/mL/min q3w
Study NCT01392807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-118
Description: 25 mg Oral tablets, single dose
Study NCT03297411 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Brief Temporoparietal ECT
Description: Electroconvulsive Therapy (Brief pulse width, Temporoparietal) The intervention in this study is different combinations of pulse width and ECT electrode placements.
Study NCT03297411 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrabrief Temporoparietal ECT
Description: Electroconvulsive Therapy (Ultrabrief pulse width, Temporoparietal) The intervention in this study is different combinations of pulse width and ECT electrode placements.
Study NCT04557852 — intervention group
Intervention type: PROCEDURE
Intervention: ATVM
Description: Tailored anterior transvaginal mesh for pelvic organ prolapse
Study NCT02416557 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEEP
Description: application of 10 cmH2O (centimeter of water) positive end expiratory pressure during mechanical ventilation
Study NCT04528121 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CoDuSe balance training and step square exercises
Description: The standardized intervention targeted visual, somatosensory, and vestibular aspects of balance and will be included with balance exercises~Examples of core stability exercises as follows: in supine position with knees bent, slowly slide one heel forward to straighten leg; and, in four-point kneeling position, slide one foot in a straight line away from the body and lift the leg off the floor.~Examples of dual-task exercises as walking while turning one's head and juggling a balloon.~Examples of sensory strategies as standing and walking on uneven surfaces and standing with eyes closed.
Study NCT04528121 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional balance training
Description: static and dynamic balance training exercises from sitting, standing and ambulation activities
Study NCT03297411 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Brief Frontoparietal ECT
Description: Electroconvulsive Therapy (Brief pulse width, Frontoparietal) The intervention in this study is different combinations of pulse width and ECT electrode placements.
Study NCT03297411 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrabrief Frontoparietal ECT
Description: Electroconvulsive Therapy (Ultrabrief pulse width, Frontoparietal) The intervention in this study is different combinations of pulse width and ECT electrode placements.
Study NCT00945828 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Annual Intervention Group
Description: Parents/caregivers and the teacher of participants will be asked to evaluate the effectiveness of the child's IEP once per academic calendar year. The evaluation is done through the use of an IEP Questionnaire developed for this study. This questionnaire addresses the child's academic performance, progress, and adherence to the IEP developed.
Study NCT00945828 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quarterly Monitoring of IEP
Description: Parents/caregivers and the teacher of participants will be asked to evaluate the effectiveness of the child's IEP four times per academic calendar year. The evaluation is done through the use of an IEP Questionnaire developed for this study. This questionnaire addresses the child's academic performance, progress, and adherence to the IEP developed.
Study NCT00661271 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Description: 8 weekly sessions with instruction designed to enhance mindfulness--mindful meditation, mindful yoga, and discussion of mindfulness practice, with one retreat session.
Study NCT02076425 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PCIT-ED
Study NCT03219775 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab/Ipilimumab
Description: * Induction: Mono-Therapy with Nivolumab (240 mg i.V. / Q2W x 4)~* If CR/PR: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W)~* If SD/PD: Nivolumab/Ipilimumab Boost 1+2-Combination Therapy (Nivo1 mg/kg i.V. and Ipi3 mg/kg i.V. / Q3W x 2)\*~* If CR/PR: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W)~* If SD/PD: Nivolumab/Ipilimumab Boost 3+4-Combination Therapy (Nivo 1 mg/kg i.V. and Ipi 3 mg/kg i.V. / Q3W x 2)~* If CR/PR/SD: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W)~  * since June 5, 2019, the treatment in all four boost cycles (1+2) and (3+4) is performed with nivolumab 1 mg/kg + ipilimumab 3 mg/kg (NIVO1/IPI3)
Study NCT00661271 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy topics
Description: 8 week health education program with one retreat session
Study NCT04279106 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 0.05%chlorhexidine mouthwash
Description: All subjects were instructed to rinse once a day, in the morning, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.